|President of Servier|
We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic advancement for the benefit of patients with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Operating in 148 countries, 21,000 collaborators employed worldwide, with a turnover of 4 billion euros in 2016. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, oncology and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 15 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative.
All our employees are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress for the benefit of patients.
we are keenly aware of our responsibilities to patients, doctors, and healthcare professionals. They are the motivating force behind our daily drive for innovation as a provider of therapeutic progress.
We are an independent Group governed by a foundation, headed by a President and an Executive Committee .
Our R&D, production, and subsidiary activities are carried out in 70 countries worldwide and our medicines are available in 148 countries.
Our medicines are used to treat 64 million patients daily. 25% of our turnover, excluding generics, is reinvested in R&D.
The sustainability of our Group is based on innovation, sharing, commitment, and caring about others.